N
ADCT icon

Nuveen’s ADC Therapeutics ADCT Stock Holding History

Nuveen’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$548K Buy
146,258
+27,343
+23% +$108K ﹤0.01% 2805
2025
Q4 		$420K Sell
118,915
-52,315
-31% -$212K ﹤0.01% 2939
2025
Q3 		$685K Buy
171,230
+52,315
+44% +$165K ﹤0.01% 2781
2025
Q2 		$319K Sell
118,915
-33,132
-22% -$69.7K ﹤0.01% 3027
2025
Q1 		$214K Hold
152,047
– – ﹤0.01% 3122
2024
Q4 		$303K Buy
152,047
+22,989
+18% +$60.2K ﹤0.01% 3128
2024
Q3 		$407K Sell
129,058
-108,246
-46% -$341K ﹤0.01% 3078
2024
Q2 		$750K Buy
+237,304
New +$943K ﹤0.01% 2850

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen's ADCT Position: Q1 2026 in Review

Nuveen increased its ADC Therapeutics (ADCT) stake by 23% in Q1 2026, buying an estimated $108K and bringing the position to 146,258 shares worth $548K. The position accounts for ﹤0.01% of the portfolio, ranked #2805.

Nuveen first reported a position in ADCT in Q2 2024 and has held it in 8 quarters since. The position peaked at $750K in Q2 2024. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Nuveen held 146,258 shares of ADC Therapeutics worth $548K as of Q1 2026.
  • Nuveen bought 27,343 ADC Therapeutics shares in Q1 2026, an estimated $108K.
  • ADC Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2805 holding.
  • Nuveen first reported a position in ADC Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Nuveen's ADC Therapeutics position peaked at $750K in Q2 2024.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.